In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Exkivity is a novel oral anti-cancer drug that acts as a small molecule tyrosine···【more】
Release date:2024-08-08Recommended:344
Capmatinib can be used to treat patients with METex14-mutated non-small cell lun···【more】
Release date:2024-08-07Recommended:339
Capmatinib is an oral MET inhibitor that received Breakthrough Therapy Designati···【more】
Release date:2024-08-07Recommended:352
Capmatinib is a targeted drug used to treat a specific type of non-small cell lu···【more】
Release date:2024-08-07Recommended:380
Capmatinib acts as a targeted therapy to stop the growth and spread of cancer ce···【more】
Release date:2024-08-07Recommended:359
Exkivity is a targeted drug for the treatment of specific types of non-small cel···【more】
Release date:2024-08-07Recommended:321
Exkivity is an oral capsule drug primarily used for the treatment of patients wi···【more】
Release date:2024-08-07Recommended:356
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) ···【more】
Release date:2024-08-07Recommended:316
Exkivity offers a new treatment option for NSCLC patients with EGFR exon 20 inse···【more】
Release date:2024-08-07Recommended:305
Capmatinib is a targeted drug manufactured by Novartis for the treatment of adul···【more】
Release date:2024-08-07Recommended:353
Exkivity provides a new treatment option for NSCLC patients with EGFR exon 20 in···【more】
Release date:2024-08-07Recommended:271
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells···【more】
Release date:2024-08-07Recommended:256